Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exosomes derived from natural killer (NK) cells cultured under hypoxic conditions are nanoscale extracellular vesicles that carry a range of bioactive molecules, including cytotoxic proteins (such as perforin, granzymes A and B, granulysin), death ligands (Fas ligand), and regulatory microRNAs. Hypoxia enhances both the production and antitumor activity of these exosomes. These vesicles can selectively target tumor cells—inducing apoptosis via caspase-dependent and independent pathways—while sparing normal healthy cells. Mechanistically, they deliver cytotoxic payloads that disrupt tumor cell membranes or trigger programmed cell death through mitochondrial and endoplasmic reticulum stress pathways. Hypoxic preconditioning of NK cells is reported to further boost the yield and potency of their secreted exosomes for potential use in cancer immunotherapy[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hypoxic NK cells-derived exosomes.